Smith, Alison E.
Ferraro, Emanuela
Safonov, Anton
Morales, Cristina Bernado
Lahuerta, Enrique J. Arenas http://orcid.org/0000-0001-7076-2666
Li, Qing
Kulick, Amanda
Ross, Dara
Solit, David B. http://orcid.org/0000-0002-6614-802X
de Stanchina, Elisa
Reis-Filho, Jorge http://orcid.org/0000-0003-2969-3173
Rosen, Neal http://orcid.org/0000-0002-8307-654X
Arribas, Joaquín http://orcid.org/0000-0002-0504-0664
Razavi, Pedram http://orcid.org/0000-0003-4236-0576
Chandarlapaty, Sarat http://orcid.org/0000-0003-4532-8053
Funding for this research was provided by:
Breast Cancer Research Foundation
Article History
Received: 3 June 2021
Accepted: 4 November 2021
First Online: 18 November 2021
Competing interests
: SC has served as a consultant for Eli Lilly, Novartis, and Sanofi. He has received prior research funding from Daiichi-Sankyo and Paige.AI. PR reports consulting or advisory role for Novartis, AstraZeneca, and Foundation Medicine and institutional research support from Illumina and GRAIL. JR-F reports personal/consultancy fees from VolitionRx, Page.AI, Goldman Sachs, Grail, Ventana Medical Systems, Roche, Genentech, and Invicro. DBS received honoraria and consulted for Pfizer, Loxo, Vividion, Illumina, and Lilly Oncology. NR is on the scientific advisory boards (SABs) of and owns equity in BeiGene, Zai Lab, MAPCure, Ribon Therapeutics, and Fortress; is on the SABs of AstraZeneca and Chugai; consults with Novartis, Boehringer Ingelheim, RevMed, Eli Lilly, and Array-Pfizer; owns equity in Kura; and receives research support from Boehringer Ingelheim, AstraZeneca, and RevMed. JA has received research funds from Roche, Synthon, Menarini, and Molecular Partners and consultancy honoraria from Menarini. The remaining authors declare no competing interests. PR reports consulting or advisory role for Novartis, AstraZeneca, and Foundation Medicine and institutional research support from Illumina and GRAIL. JR-F reports personal/consultancy fees from VolitionRx, Page.AI, Goldman Sachs, Grail, Ventana Medical Systems, Roche, Genentech, and Invicro. DBS received honoraria and consulted for Pfizer, Loxo, Vividion, Illumina, and Lilly Oncology. NR is on the scientific advisory boards (SABs) of and owns equity in BeiGene, Zai Lab, MAPCure, Ribon Therapeutics, and Fortress; is on the SABs of AstraZeneca and Chugai; consults with Novartis, Boehringer Ingelheim, RevMed, Eli Lilly, and Array-Pfizer; owns equity in Kura; and receives research support from Boehringer Ingelheim, AstraZeneca, and RevMed. JA has received research funds from Roche, Synthon, Menarini, and Molecular Partners and consultancy honoraria from Menarini. The remaining authors declare no competing interests.